Investors & Partners
We welcome enquiries from potential new investors and partners in dianax, as we continue to raise funds to support the development and commercialization process.
Your chance to invest ...
Crowdfunding campaign is live!
With dianax lab-on-a-chip, POINT OF NEED testing is becoming a reality and thanks to our NEW CROWDFUNDING* CAMPAIGN, you could be part of its future.
Diagnostics in the palm of your hand … from a drop of blood to final results in under five minutes.
Microfluidics-based POINT OF NEED testing is one of the fastest-growing segments of the in-vitro diagnostics market and integral to the diagnosis, management and monitoring of many chronic diseases, including diabetes. Freeing people from endless trips to the doctor or hospital and empowering them to monitor their own health ‘on the go’ has the potential to not only change lives, but also improve patient outcomes.
Our aim is to capture a significant share of this large and growing market.
A minimum €500 investment is all it takes**… to sign up or find out more, visit backtowork24
*Equity crowdfunding is a form of investment that allows a group of investors to finance start-ups and SMEs through online portals authorized by Consob, providing a loan in exchange for company shares of the same company. For Italian tax resident investors, tax breaks are envisaged of up to 40% of the amount invested in innovative start-ups and SMEs.
**Information found on the Backtowork24 portal is not subject to approval by Consob (Italian authority for the supervision of financial markets). The issuer is solely responsible for the completeness and truthfulness of the data and information provided. Please note that investment in financial instruments issued by innovative start-ups is illiquid and characterized as very high risk.
The goal is to shrink down to a single silicon chip all of the processes necessary to analyze a disease that would normally be carried out in a full-scale biochemistry lab”
Numbers that pack a punch
Microfluidics-based POINT OF NEED testing is one of the fastest-growing segments of the in vitro diagnostics market:1
Our dianax lab-on-a-chip* technology and value proposition could capture a significant share of this large and growing market.
worldwide annual growth rate
the global value Microfluidic-based PoN tests market is expected to surpass by 2023
spent since 2014 in fundraising, mergers and acquisitions
Chartering new territory
The future of sustainable healthcare is dependent on diagnostics. It plays a critical role in decision-making across the entire health continuum and sits at the heart of the ongoing healthcare revolution:
De-centralization & patient-centricity
We welcome new investors
The dianax board of directors, clinical advisory team, partners and investors are highly respected in the healthcare and venture capital industries. They passionately support, advise and guide us in our quest to become the leading lab-on-a-chip diagnostics company.
Designed to facilitate ‘breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market’, the Horizon 2020 grant underscores the terrific potential of our technology in changing the face of diagnostic testing.
We welcome new partners
Find out more
*Products/devices are under development but not yet approved for use. For investigational use only.
1. ©2018 | www.yole.fr | Point-of-Need Testing: Application of Microfluidic Technologies